The U.S. Centers for Medicare & Medicaid Services has posted the home health final rule for calendar year 2026 and has established a framework for competitive bidding for products such as continuous glucose monitors, a move that is struggling to find support among stakeholders.
Di’ao Group Chengdu Pharmaceutical Co. Ltd. has identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, dementia, obesity, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD), dyslipidemia, stroke and cardiovascular disorders, among others.
University of Notre Dame du Lac has disclosed peptide-drug conjugates, their hydrogels and their self-assembling nanofibers comprising glucagon-like peptide 1 receptor (GLP-1R) and/or gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor agonists linked to an amphiphile moiety through a hydrophobic or hydrophilic-comprising linker acting as vaccine adjuvants reported to be useful for the treatment of diabetes and obesity.
Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.
Diabetic retinopathy (DR) is a leading cause of vision loss in patients with diabetes, with limited therapeutic options. While current treatments focus on the proliferative stage, there is an urgent need to understand the underlying mechanisms of the early stages of DR to halt progression. Growing research suggests that activated microglia are key drivers of inflammation in DR.
Single agonists of the glucagon-like peptide-1 receptor (GLP-1R) have been a success in the treatment of obesity, but monomeric dual or triple agonists have demonstrated improved efficacy on energy intake, appetite or metabolic function.
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, energy expenditure and glucose metabolism. However, its short plasma half-life limits its therapeutic potential.
Eluciderm Inc. has received clearance from the U.S. FDA for its IND to conduct a phase I/IIa open-label study evaluating the safety and efficacy of ELU-42, a topical spray-on solution for open wound healing, in patients with diabetic foot ulcers (DFUs).
Insparin is a protein isolated from human adenovirus Ad36 that induces cellular glucose uptake without impacting safety. A preclinical study of insparin looked at its potential antidiabetic effects compared to those of pioglitazone.
